Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Similar articles for PubMed (Select 15150605)

1.

Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions.

Clavel C, Cucherousset J, Lorenzato M, Caudroy S, Nou JM, Nazeyrollas P, Polette M, Bory JP, Gabriel R, Quereux C, Birembaut P.

Br J Cancer. 2004 May 4;90(9):1803-8.

2.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
3.

Use of high-risk human papillomavirus testing in patients with low-grade squamous intraepithelial lesions.

Levi AW, Harigopal M, Hui P, Schofield K, Chhieng DC.

Cancer Cytopathol. 2011 Aug 25;119(4):228-34. doi: 10.1002/cncy.20172. Epub 2011 Jul 5.

PMID:
21732551
4.
5.

Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.

Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.

Br J Cancer. 2001 Jun 15;84(12):1616-23.

6.

[Human papillomavirus typing in routine cervical smears. Results from a series of 3778 patients].

Levert M, Clavel C, Graesslin O, Masure M, Birembaut P, Quereux C, Gabriel R.

Gynecol Obstet Fertil. 2000 Oct;28(10):722-8. French.

PMID:
11244634
7.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

8.

Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study.

Dalstein V, Riethmuller D, Prétet JL, Le Bail Carval K, Sautière JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C.

Int J Cancer. 2003 Sep 1;106(3):396-403.

PMID:
12845680
9.

Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.

Clavel C, Masure M, Levert M, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P.

Diagn Mol Pathol. 2000 Sep;9(3):145-50.

PMID:
10976721
10.

The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.

Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS.

Eur J Gynaecol Oncol. 1998;19(3):203-8.

PMID:
9641214
11.

High-risk HPV DNA detection by Hybrid Capture II. An adjunctive test for mildly abnormal cytologic smears in women > or = 50 years of age.

Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS.

J Reprod Med. 2000 Apr;45(4):345-50.

PMID:
10804494
13.

Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.

Sellors JW, Lorincz AT, Mahony JB, Mielzynska I, Lytwyn A, Roth P, Howard M, Chong S, Daya D, Chapman W, Chernesky M.

CMAJ. 2000 Sep 5;163(5):513-8.

14.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

15.

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.

Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061.

PMID:
18573778
16.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

PMID:
16978225
17.

Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening.

Huang YK, You SL, Yuan CC, Ke YM, Cao JM, Liao CY, Wu CH, Hsu CS, Huang KF, Lu CH, Twu NF, Chu TY.

Br J Cancer. 2008 Mar 11;98(5):863-9. doi: 10.1038/sj.bjc.6604262. Epub 2008 Feb 19.

18.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

19.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
20.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk